BT-595 is under clinical development by Biotest and currently in Phase III for Primary Immune Deficiency (PID). According to GlobalData, Phase III drugs for Primary Immune Deficiency (PID) have a 67% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how BT-595’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
BT-595 is under development for the treatment of primary immune deficiency (PID), idiopathic thrombocytopenic purpura and scleromyxedema (dermatology). It is administered by intravenous route as solution. The drug candidate is a polyvalent human immunoglobulin.
Biotest, a subsidiary of Grifols SA, provides pharmaceutical and biotherapeutic drugs. It develops, manufactures and distributes biological medicines through its value chain from preclinical and clinical development to sales. Its main products include clotting factors, immunoglobulins, albumin and monoclonal antibodies in clinical development. The company specializes in the areas of clinical immunology, haematology and intensive care medicine. Biotest distributes its products through local marketing partners and distributors in Europe, North America, South America, Asia, the Middle East and Africa. It has subsidiaries and sales companies in Austria, Switzerland, France, Great Britain, Italy, Hungary and Spain and Brazil. Biotest is headquartered in Dreieich, Hessen, Germany.
For a complete picture of BT-595’s drug-specific PTSR and LoA scores, buy the report here.